A
Alan Rembach
Researcher at University of Melbourne
Publications - 69
Citations - 3823
Alan Rembach is an academic researcher from University of Melbourne. The author has contributed to research in topics: Dementia & Cognitive decline. The author has an hindex of 33, co-authored 68 publications receiving 3262 citations. Previous affiliations of Alan Rembach include Florey Institute of Neuroscience and Mental Health & Commonwealth Scientific and Industrial Research Organisation.
Papers
More filters
Journal ArticleDOI
Blood-Based Protein Biomarkers for Diagnosis of Alzheimer Disease
James D. Doecke,James D. Doecke,Simon M. Laws,Simon M. Laws,Noel G. Faux,Noel G. Faux,William Wilson,Samantha C. Burnham,Chiou Peng Lam,Alinda Mondal,Alinda Mondal,Justin Bedo,Ashley I. Bush,Ashley I. Bush,Belinda M. Brown,Belinda M. Brown,Karl De Ruyck,Karl De Ruyck,Kathryn A. Ellis,Christopher Fowler,Veer Bala Gupta,Veer Bala Gupta,Richard Head,S. Lance Macaulay,Kelly K. Pertile,Christopher C. Rowe,Alan Rembach,Mark Rodrigues,Mark Rodrigues,Rebecca L. Rumble,Cassandra Szoeke,Kevin Taddei,Kevin Taddei,Tania Taddei,Tania Taddei,Brett Trounson,David Ames,Colin L. Masters,Colin L. Masters,Ralph N. Martins,Ralph N. Martins +40 more
TL;DR: This study identified a panel of plasma biomarkers that distinguish individuals with AD from cognitively healthy control subjects with high sensitivity and specificity.
Journal ArticleDOI
PBT2 Rapidly Improves Cognition in Alzheimer's Disease: Additional Phase II Analyses
Noel G. Faux,Craig W. Ritchie,Adam P Gunn,Alan Rembach,Alan Rembach,Andrew Tsatsanis,Justin Bedo,John Harrison,Lars Lannfelt,Kaj Blennow,Henrik Zetterberg,Martin Ingelsson,Colin L. Masters,Rudolph E. Tanzi,Jeffrey L. Cummings,Caroline M. Herd,Ashley I. Bush +16 more
TL;DR: Receiver-operator characteristic analyses and ranking the responses to treatment after 12 weeks revealed that the proportions of patients showing improvement on NTB Composite or Executive Factor z-scores were significantly greater in the PBT2 250 mg group than in the placebo group, which further encourage larger-scale testing of P BT2 for AD.
Journal ArticleDOI
Induction of the Unfolded Protein Response in Familial Amyotrophic Lateral Sclerosis and Association of Protein-disulfide Isomerase with Superoxide Dismutase 1
Julie D. Atkin,Manal A. Farg,Bradley J. Turner,Doris Tomas,Judith A. Lysaght,Janelle Nunan,Alan Rembach,Phillip Nagley,Philip M Beart,Surindar S Cheema,Malcolm K. Horne +10 more
TL;DR: These findings implicate unfolded protein response and ER stress-induced apoptosis in the patho-physiology of familial ALS and the possibility that PDI may be a therapeutic target to prevent SOD1 aggregation is raised.
Journal ArticleDOI
Impaired Extracellular Secretion of Mutant Superoxide Dismutase 1 Associates with Neurotoxicity in Familial Amyotrophic Lateral Sclerosis
Bradley J. Turner,Julie D. Atkin,Manal A. Farg,Da Wei Zang,Alan Rembach,Elizabeth C Lopes,Justin D Patch,Andrew F. Hill,Surindar S Cheema +8 more
TL;DR: It is demonstrated that a fraction of active endogenous SOD1 is secreted by NSC-34 motor neuron-like cells via a brefeldin-A (BFA)-sensitive pathway and this results suggest novel extracellular roles for S OD1 in ALS and support a causal relationship between mutant Sod1 secretion and intraneuronal toxicity.
Journal ArticleDOI
Plasma Amyloid-β as a Biomarker in Alzheimer's Disease: The AIBL Study of Aging
James Lui,James Lui,Simon M. Laws,Simon M. Laws,Qiao-Xin Li,Victor L. Villemagne,David Ames,Belinda M. Brown,Belinda M. Brown,Ashley I. Bush,Karl De Ruyck,Karl De Ruyck,Jasmin Dromey,Kathryn A. Ellis,Noel G. Faux,Jonathan K. Foster,Jonathan K. Foster,Christopher Fowler,Veer Bala Gupta,Veer Bala Gupta,Peter J. Hudson,Peter J. Hudson,Katrina M. Laughton,Colin L. Masters,Kelly K. Pertile,Alan Rembach,Mira Rimajova,Mira Rimajova,Mark Rodrigues,Mark Rodrigues,Christopher C. Rowe,Rebecca L. Rumble,Cassandra Szoeke,Kevin Taddei,Kevin Taddei,Tania Taddei,Tania Taddei,Brett Trounson,Vanessa Ward,Vanessa Ward,Ralph N. Martins,Ralph N. Martins +41 more
TL;DR: The cross-sectional analysis of plasma Abeta isoforms suggests that they may not be sufficient per se to diagnose AD, and the value of their measurement in prognosis and monitoring of AD interventions needs further study.